ENSG
NEUTRAL
$204.79
Live
The Ensign Group, Inc. · NASDAQ
Target $220.4
(+7.6%)
$118.73
52W Range
$218.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 09, 2026
Market cap
$11.96B
P/E
34.36
ROE
16.9%
Profit margin
6.8%
Debt/Equity
0.99
Dividend yield
0.13%
AI Analysis
AI-powered fundamental assessment
Confidence
80%
ENSG shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 5/9). Mixed signals with both opportunities and risks present.
Key Strengths
Strong revenue growth of 20.2%
Strong ROE of 16.9%
Key Risks
High valuation with P/E of 34.4
Premium vs Graham Number ($72.05)
AI Fair Value Estimate
Based on comprehensive analysis
$175.82
-14.1% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
47
Moderate
35
65
60
50
25
AI Verdict
ENSG shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 5/9). Mixed signals with both opportunities and risks present.
Key drivers: Strong revenue growth of 20.2%, Strong ROE of 16.9%, High valuation with P/E of 34.4
Confidence
60%
Value
35/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Premium 34.4x trailing earnings multiple.
- Trades above Graham Number.
Future
65/100
Rule-based growth outlook.
Positives
- Revenue growth running at 20.2%.
Watchpoints
No urgent risks highlighted.
Past
60/100
Historical performance + price trend: Shares moved +121.6% over 5Y and +65.7% over 1Y.
Positives
- ROE sits at 16.9%.
Watchpoints
No urgent risks highlighted.
Health
50/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Dividend
25/100
Dividend policy fallback.
Positives
- Yield: 0.1%.
Watchpoints
- Weak dividend profile (Score: 25/100).
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$204.79
Analyst Target
$220.4
Upside/Downside
+7.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ENSG and closest competitors.
Updated 2026-04-08
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ENSG
The Ensign Group, Inc.
Primary
|
+121.6% | +109.3% | +65.7% | +16.2% | -2.4% | +2.3% |
|
EXEL
Exelixis, Inc.
Peer
|
+91.2% | +119.8% | +29.5% | +14.4% | +4.3% | +0.4% |
|
ALGN
Align Technology, Inc.
Peer
|
-70.6% | -48.8% | +2.3% | +24.8% | -16.9% | -5.6% |
|
BMRN
BioMarin Pharmaceutical Inc.
Peer
|
-27.4% | -41.9% | -20.1% | +4.3% | -5.4% | +4.4% |
|
NBIX
Neurocrine Biosciences, Inc.
Peer
|
+34.2% | +30.1% | +19.1% | -6.2% | -0.5% | +3.0% |
ENS
The Ensign Group, Inc.
Primary
5Y
+121.6%
3Y
+109.3%
1Y
+65.7%
6M
+16.2%
1M
-2.4%
1W
+2.3%
EXE
Exelixis, Inc.
Peer
5Y
+91.2%
3Y
+119.8%
1Y
+29.5%
6M
+14.4%
1M
+4.3%
1W
+0.4%
ALG
Align Technology, Inc.
Peer
5Y
-70.6%
3Y
-48.8%
1Y
+2.3%
6M
+24.8%
1M
-16.9%
1W
-5.6%
BMR
BioMarin Pharmaceutical Inc.
Peer
5Y
-27.4%
3Y
-41.9%
1Y
-20.1%
6M
+4.3%
1M
-5.4%
1W
+4.4%
NBI
Neurocrine Biosciences, Inc.
Peer
5Y
+34.2%
3Y
+30.1%
1Y
+19.1%
6M
-6.2%
1M
-0.5%
1W
+3.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
34.36
Forward P/E
24.86
PEG Ratio
1.75
P/B Ratio
5.29
P/S Ratio
2.37
EV/Revenue
2.66
EV/EBITDA
25.44
Market Cap
$11.96B
Profitability
Profit margins and return metrics
Profit Margin
6.8%
Operating Margin
9.1%
Gross Margin
16.34%
ROE
16.89%
ROA
5.25%
Growth
Revenue and earnings growth rates
Revenue Growth
+20.2%
Earnings Growth
+18.4%
Q/Q Revenue Growth
+20.17%
Q/Q Earnings Growth
+19.8%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.99
Moderate
Current Ratio
1.42
Good
Quick Ratio
1.35
Good
Cash/Share
$9.92
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$1.4B
Gross Margin
16.3%
Op. Margin
9.1%
Net Margin
7.0%
Total Assets
$5.5B
Liabilities
$3.2B
Equity
$2.2B
Debt/Equity
1.45x
Operating CF
$0.2B
Free Cash Flow
$0.4B
FCF Yield
204%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-28
$N/A
2026-02-04
$1.82
+3.0% surprise
2025-11-03
$1.64
+2.1% surprise
2025-07-24
$1.59
+2.6% surprise
Healthcare Sector Comparison
Comparing ENSG against 189 companies in the Healthcare sector
(17 bullish, 63 neutral, 109 bearish)
P/E Ratio
34.36
This Stock
vs
45.52
Sector Avg
-24.5%
(Discount)
Return on Equity (ROE)
16.89%
This Stock
vs
-44.08%
Sector Avg
-138.3%
(Below Avg)
Profit Margin
6.8%
This Stock
vs
-19.57%
Sector Avg
-134.8%
(Weaker)
Debt to Equity
0.99
This Stock
vs
5.1
Sector Avg
-80.6%
(Less Debt)
Revenue Growth
20.2%
This Stock
vs
108.17%
Sector Avg
-81.3%
(Slower)
Current Ratio
1.42
This Stock
vs
3.39
Sector Avg
-58.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ENSG
The Ensign Group, Inc.
|
NEUTRAL | $11.96B | 34.36 | 16.9% | 6.8% | $204.79 | |
|
EXEL
Exelixis, Inc.
|
BULLISH | $11.85B | 15.84 | 35.5% | 33.7% | $44.2 | Compare |
|
ALGN
Align Technology, Inc.
|
NEUTRAL | $11.78B | 29.07 | 10.4% | 10.2% | $164.23 | Compare |
|
BMRN
BioMarin Pharmaceutical Inc.
|
NEUTRAL | $10.86B | 32.28 | 5.9% | 10.8% | $56.49 | Compare |
|
NBIX
Neurocrine Biosciences, Inc.
|
BULLISH | $13.22B | 28.15 | 16.4% | 16.7% | $131.74 | Compare |
ENSG
The Ensign Group, Inc.
NEUTRAL
Mkt Cap
$12.0B
P/E
34.4
ROE
16.9%
Price
$204.79
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-02 | SMITH BARRY M | Director | Sale | 700 | $137,655 |
| 2026-03-02 | SMITH BARRY M | Director | Sale | 700 | $149,114 |
| 2026-02-26 | KEETCH CHAD A | Chief Investment Officer | Stock Award | 8,000 | - |
| 2026-02-26 | BURTON SPENCER W | President | Stock Award | 8,500 | - |
| 2026-02-26 | SNAPPER SUZANNE D. | Chief Financial Officer | Stock Award | 9,000 | - |
| 2026-02-26 | WITTEKIND BEVERLY B | Officer | Stock Award | 1,000 | - |
| 2026-02-26 | PORT BARRY R | Chief Executive Officer | Stock Award | 12,000 | - |
| 2026-02-20 | UYCHIAT PISON MARIVIC | Director | Sale | 150 | $31,244 |
| 2026-02-19 | WITTEKIND BEVERLY B | Officer | Sale | 500 | $105,115 |
| 2026-02-19 | WITTEKIND BEVERLY B | Officer | Option Exercise | 500 | $41,820 |
| 2026-02-18 | KEETCH CHAD A | Chief Investment Officer | Stock Award | 8,340 | $1,751,066 |
| 2026-02-18 | BURTON SPENCER W | President | Stock Award | 9,701 | $2,036,822 |
| 2026-02-18 | SNAPPER SUZANNE D. | Chief Financial Officer | Stock Award | 11,983 | $2,515,951 |
| 2026-02-18 | PORT BARRY R | Chief Executive Officer | Stock Award | 13,871 | $2,912,355 |
| 2026-02-17 | SHAW DAREN J | Director | Sale | 1,000 | $213,430 |
SMITH BARRY M
Director
2026-04-02
700 shares
·
$137,655
SMITH BARRY M
Director
2026-03-02
700 shares
·
$149,114
KEETCH CHAD A
Chief Investment Officer
2026-02-26
8,000 shares
BURTON SPENCER W
President
2026-02-26
8,500 shares
SNAPPER SUZANNE D.
Chief Financial Officer
2026-02-26
9,000 shares
WITTEKIND BEVERLY B
Officer
2026-02-26
1,000 shares
PORT BARRY R
Chief Executive Officer
2026-02-26
12,000 shares
UYCHIAT PISON MARIVIC
Director
2026-02-20
150 shares
·
$31,244
WITTEKIND BEVERLY B
Officer
2026-02-19
500 shares
·
$105,115
WITTEKIND BEVERLY B
Officer
2026-02-19
500 shares
·
$41,820
KEETCH CHAD A
Chief Investment Officer
2026-02-18
8,340 shares
·
$1,751,066
BURTON SPENCER W
President
2026-02-18
9,701 shares
·
$2,036,822
SNAPPER SUZANNE D.
Chief Financial Officer
2026-02-18
11,983 shares
·
$2,515,951
PORT BARRY R
Chief Executive Officer
2026-02-18
13,871 shares
·
$2,912,355
SHAW DAREN J
Director
2026-02-17
1,000 shares
·
$213,430
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
5 analysts
RBC Capital
2026-02-09
Outperform
Outperform
Truist Securities
2026-02-06
Hold
Hold
RBC Capital
2025-11-14
Outperform
Outperform
Truist Securities
2025-11-10
Hold
Hold
UBS
2025-11-05
Buy
Buy
Stephens & Co.
2025-11-05
Overweight
Overweight
Past News Coverage
Recent headlines mentioning ENSG from our newsroom.
Newest → oldest
No matching news yet.